Orotomide

They were discovered in 2015 by British scientists at the pharmaceutical company F2G Ltd.[1] while searching for a new drug for Aspergillus infection.

The discovery was formally announced at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) 55th meeting during 17-21 September 2015 at San Diego, California,[2] and published the next year in the Proceedings of the National Academy of Sciences.

[3] It was found to be effective against most important human fungal infections including those with Aspergillus, Lemontospora (Scedosporium) prolificans, Fusarium, Penicillium spp., and Taloromyces.

[4] Unlike other antifungal drugs, the orotomides act differently by stopping pyrimidine biosynthesis in fungal cells.

[3] The European Medicines Agency (EMA) Committee for Orphan Medicinal Products granted orphan designation to F2G for F901318 for the treatment of scedosporiosis on 29 August 2016,[6] and for invasive aspergillosis on 14 October 2016.